Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Status:
Not yet recruiting
Trial end date:
2024-07-03
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose
absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.
This is a randomized, placebo controlled, acute crossover study of empagliflozin in an
anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30
patients where they will receive empagliflozin daily.